

2nd Annual

MarketsandMarkets Next Gen Immuno-Oncology Congress

19th - 20th September 2019 • Philadelphia-USA

Event overview

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It's clearly one of the hottest field of Biopharma which has gained momentum in the past few years.

After our successful edition last year, we are coming up with the **“2nd Annual Next-Gen Immuno-Oncology Congress”** on **19 - 20 September, Philadelphia, USA** which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC's, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

Key Highlights

- Updates in development of monoclonal Abs and bispecific Abs
- Immune Checkpoint Inhibitors and Combinations
- Preclinical and Translational Immuno-Oncology Developments
- Biomarkers and Cancer Vaccines
- Next Gen CAR-T cell therapy, T-Cell Therapy
- Tumor microenvironment
- Oncolytic Viruses

Why Attend?

- Find out new case studies of antibody projects in development
- Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
- Explore the latest platforms and technologies on the market for development
- Discuss the best tool for your research in immune-oncology
- Share your work and achievements with your industry peers in the Poster Session

Who Should Attend?

Monoclonal and Bispecific Antibodies	Cell Therapy	Immune Checkpoint Inhibitors
• ADCs development Preclinical and Translational Oncology • Oncology • Bi-specifics- Preclinical and Translational • Clinical development • R&D- Discovery and process • PKPD/ADME/Tox • Antibody Engineering • Antibody therapeutics • Physio-Chemistry /Synthetic Chemistry and/ Bio conjugation • Bioanalysis	• Oncology • Clinical development • R&D- discovery and process • Discovery • Target Validation • Bioanalysis • Therapeutic areas • PKPD/ADME/Tox • Biologics -antibody • Cell-Based Immunotherapies • Innate and adaptive immune cells • Antibody engineering Tumour antigens and neoantigens	• Cancer immunotherapy • Immune checkpoint targets • Checkpoint inhibition • Cellular therapy • Clinical research • Combination therapy • Cancer Vaccines • Preclinical and Translational Oncology R&D • Immune biomarkers • Immunology • Cancer biology • Immuno-oncology • Tumour-associated mechanisms of immune suppression

2nd Annual

MarketsandMarkets Next Gen Immuno-Oncology Congress

19th - 20th September 2019 • Philadelphia-USA

Scientific Advisory Board

- **Rakesh Dixit**, President & CEO, **Bionavigen**
- **Stefan Glueck**, Senior Vice President, **Global Medical Affairs, Celgene**

Speakers panel

- **Roy Baynes**, Senior Vice President, Global Clinical Development, **Chief Medical Officer, Merck**
- **Rakesh Dixit**, CEO, **Bionavigen**
- **Stefan Glueck**, Senior Vice President, **Global Medical Affairs, Celgene**
- **Shahram Salek-Ardakani**, Senior Director, **Cancer Immunology, Pfizer**
- **Joost Oppenheim**, Head, **Cellular Immunology, NIH**
- **Carl Morrison**, President, Chief Medical Officer, **OmniSeq**
- **Scott Durum**, Head, **Cytokines and Immunity, NIH**
- **David Szymkowski**, Vice President, **Cell Biology, Xencor**
- **Li Peng**, Senior Vice President, **Discovery and Early Product Development, Palleon Pharma**
- **Sebastien Tabruyn**, Chief Scientific Officer, **Transcure Bioservices**
- **Natalie Russi**, Scientific Project Manager, **Nebion**
- **Senior Representative, Biocytogen**
- **Emmanuel Normant**, Vice President, **Preclinical Sciences, TG Therapeutics**
- **John Rossi**, Director, **Translational Sciences, Kite Pharma**
- **Joyson Karakunnel**, Vice President, Head, Clinical Development, **Arcus Biosciences**
- **Rajesh Singh**, Laboratory Director, **Abzyme Therapeutics**
- **Mihail Obrocea**, Senior Medical Director, **Juno Therapeutics**
- **Kevin Wufeng Wu**, Senior Medical Director, Global Medicines Development Immunotherapy, **AstraZeneca**
- **Melissa Olekson**, Scientific Support Specialist, **PromoCell**
- **Tahamtan Ahmadi**, Senior Vice President, **Genmab**
- **Steven Nadler**, Vice President, Discovery and Translational Research, **Aro Biotherapeutics**

Gold Sponsor



Sponsors & Exhibitors



2nd Annual

MarketsandMarkets Next Gen Immuno-Oncology Congress

19th - 20th September 2019 • Philadelphia-USA

Day 1 - September 19th 2019

08:15 Registration

08:55 Welcome note from MarketsandMarkets

STREAM A	STREAM B
Monoclonal and Bispecific Antibodies	Immune Checkpoint Inhibitors & Combination Strategies
9:00 Opening remarks from the Chairman	9:00 Opening remarks from the Chairman
9:05 Keynote: Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics • A review of the most promising combinations in cancer immunotherapies • What combinations have worked well and potential MOAs? • What combinations have failed or too toxic? • How successful combinations can help generate the best bispecific biologics? Rakesh Dixit , President & CEO, Bionavigen	9:05 Anti PD-1 Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy • Pembrolizumab has demonstrated broad spectrum anticancer monotherapy activity • Precision medicine tools have enriched for patients most likely to respond to monotherapy and helped define combination therapy strategies • Pembrolizumab in combination with other agents has established favorable benefit risk profiles in a number of cancers Roy Baynes , Senior Vice President, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
9:35 Increasing specificity of targeting employing bispecific antibodies	9:35 CPI combination with chemotherapy and radiation
10:05 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings	
Targeted Antibodies and Combinations	Pre-clinical & Translational Immuno-Oncology Developments
11:25 Novel conjugation technologies-Payload and Linkers	11:25 Pre-clinical models for Immune Checkpoint Modulators
11:55 Improving recruitment of myeloid effector cells for antibody therapy	11:55 Creating novel hypotheses and evaluation in translational research
12:25 Therapeutic targeting of the tumor microenvironment	12:25 Humanized Mouse Models for Immuno-Oncology Research • Car-T cell therapy • Cancer Vaccines • Combination therapy (immune check point inhibitor) • PDX Sebastien Tabruyn , Chief Scientific Officer, Transcure Bioservices
12:55 Lunch and Poster Presentations One-to-One Networking Meetings	

2nd Annual

MarketsandMarkets Next Gen Immuno-Oncology Congress

19th - 20th September 2019 • Philadelphia-USA

Day 1 - September 19th 2019

STREAM A	STREAM B
Monoclonal, Bispecific Antibodies and Cellular Therapy	Immune Checkpoint Inhibitors
New Antibody Formats and Developments in CAR-T Cell Therapy	New Immune Checkpoints for Immunotherapy
13:55 Monoclonal antibody approaches for triple-negative breast cancer	13:55 Update on ICI data in early and metastatic breast cancer Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene
14:35 Bispecific T-Cell engagers for cancer immunotherapy	14:35 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com
15:05 Synthetic Biology in Cellular Immunotherapy	15:05 Panel Discussion: Future of Biologics in Immune Checkpoint therapy
15:35 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com	15:35 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com
16:05 Evening Refreshments and Poster Presentations One-to-One Networking Meetings	
16:55 Novel Bispecific PD-1 antibody therapeutic approach in solid tumours	16:55 Agonist checkpoint combination studies
17:25 Bicycle Drug Conjugate for treatment of solid tumours	17:25 Biomarkers for prognosis and prediction to immunotherapies

17:55 Closing remarks from the Chairman

18:00 Cocktail Reception | End of Day 1

2nd Annual

MarketsandMarkets Next Gen Immuno-Oncology Congress

19th - 20th September 2019 • Philadelphia-USA

Day 2 - September 20th 2019

08:15 Registration

08:55 Welcome note from MarketsandMarkets

STREAM A	STREAM B
Monoclonal and Bispecific Antibodies	Immune Checkpoint Inhibitors and Cellular Therapy
9:00 Opening remarks from the Chairman	9:00 Opening remarks from the Chairman
New Antibodies Development and Tumor Microenvironment	Personalized Immunotherapy and T-Cell Therapies
9:05 Keynote: Tumor Inflammatory Signature • Different approaches • Baseline for precision combination immunotherapy • Response to checkpoint inhibitors Carl Morrison , President, Chief Medical Officer, OmniSeq	9:05 Keynote: Improving efficacy of CPI's by selected combination therapy
9:35 Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective • TG Therapeutic pipeline is focused on heme oncology diseases like CLL or NHL • The 5 assets currently in clinic bear a strong potential for effective "wholly owned" (or intra-pipeline) combinations • Preclinical data showing CD19-CD47 bispecific antibody TG-1801, ublituximab (anti CD-20) and umbralisib (PI3Kd inhibitor) synergistic effects Emmanuel Normant , Vice President, Preclinical Sciences, TG Therapeutics	9:35 Development of effective immunotherapeutic combinations with antitumor activities • Synergistic immunostimulating effects of TLR4 and 7/8 ligands and checkpoint inhibitors • Identification of immunostimulating alarmin with causal role in Parkinson's Disease Joost Oppenheim , Head, Cellular Immunology, NIH
10:05 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings	
11:25 Recombinant antibodies for immunotherapy	11:25 Comparing immunological marker signatures across various cancer types • Analyze immune-cell induced gene expression patterns in cancer tissues • Globally normalized public data sets provide novel insights to drug response patterns Natalie Russi , Scientific Project Manager, Nebion
11:55 Understanding drug interaction potential for antibody drug conjugates in clinical development	11:55 Systematic Approaches to Identifying and Overcoming Resistance to Immune Checkpoint Inhibitors
12:25 Role of Immune Activation Profiling in clinical trials	12:25 Oncolytic viruses in the era of Checkpoint Blockade
12:55 Lunch and Poster Presentations One-to-One Networking Meetings	
13:55 Study of cytotoxic payloads-in vivo assays and efficacy testing	13:55 Role of Nanotechnology with a combinatorial approach for solid tumors
14:25 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com	14:25 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com
14:55 Predicting the toxicity of Immuno-Oncology studies	14:55 Future opportunities in clinical development of ICI combinations

15:25 Closing remarks from the Chairman

15:30 End of Conference